Besins Healthcare: Difference between revisions
Content deleted Content added
WalterWari (talk | contribs) |
mNo edit summary Tags: Reverted references removed Visual edit |
||
| Line 1: | Line 1: | ||
{{notability|Companies|date=February 2013}} |
{{notability|Companies|date=February 2013}} |
||
Besins Healthcare, a privately held pharmaceutical company, was established in 1885 by Abel Besins and Joseph Lebeau in Paris, France. Today, the company's headquarters are located in Monaco. Specialising in hormone replacement therapies, Besins Healthcare addresses health issues related to fertility, menopause and testosterone deficiency.<ref>{{Cite journal |last=Makar |first=A. B. |last2=McMartin |first2=K. E. |last3=Palese |first3=M. |last4=Tephly |first4=T. R. |date=1975-06 |title=Formate assay in body fluids: application in methanol poisoning |url=https://pubmed.ncbi.nlm.nih.gov/1 |journal=Biochemical Medicine |volume=13 |issue=2 |pages=117–126 |doi=10.1016/0006-2944(75)90147-7 |issn=0006-2944 |pmid=1}}</ref> Over the past two decades, it has expanded its operations internationally, now having a direct presence in 22 countries and distributing products in over 100 markets.<ref name=":0">{{Cite journal |last=Bose |first=K. S. |last2=Sarma |first2=R. H. |date=1975-10-27 |title=Delineation of the intimate details of the backbone conformation of pyridine nucleotide coenzymes in aqueous solution |url=https://pubmed.ncbi.nlm.nih.gov/2 |journal=Biochemical and Biophysical Research Communications |volume=66 |issue=4 |pages=1173–1179 |doi=10.1016/0006-291x(75)90482-9 |issn=1090-2104 |pmid=2}}</ref> Besins Healthcare operates through its fully owned affiliate, Ascend Therapeutics, in the US..<ref name=":0" /> |
|||
'''Besins Healthcare''' is a [[Private equity|privately]] held, fifth-generation [[Family business|family-owned]] [[Multinational corporation|multinational]] [[Pharmaceutical industry|pharmaceutical company]] headquartered in Monaco. Founded in 1885 in [[Paris]], Besins Healthcare focuses on transdermal delivery technology treatments and has products available in 100 countries. |
|||
The company reports a revenue of €500 million in 2023 and employs more than 1,500 individuals globally. |
|||
The company specializes in Women’s and Men’s Health and is manufacturing and developing drugs for the treatment of [[gynecological]], [[fertility]], and obstetrical conditions as well as androgen deficiencies.<ref name="Washpost group">{{cite news|last=Flandez|first=Ramon|title=For Ascend Therapeutics, Success Is Only Skin Deep|url=https://www.washingtonpost.com/wp-dyn/articles/A28153-2004Jul4.html|newspaper=[[The Washington Post]]|access-date=June 19, 2012|date=July 5, 2004}}</ref> Besins Healthcare has three subsidiaries: BHR Pharma, LLC, Ascend Therapeutics and Pure Matters. |
|||
Ascend Therapeutics is involved in the research and development of transdermal drugs that are applied to the skin as a gel to treat chronic conditions such as severe breast pain for [[pre-menopausal]] women, and low [[testosterone]] levels for older men.<ref name="Washpost group"/> |
|||
Besins Healthcare global research and development is conducted out of BHR Pharma, and LLC. BHR Pharma is in the last stage of human testing of a potential [[progesterone]]-based treatment (BHR-100) for severe [[traumatic brain injury]] (TBI).<ref>{{cite journal|title=Efficacy and Safety Study of Intravenous Progesterone in Patients With Severe Traumatic Brain Injury (SyNAPSe)|url=https://www.clinicaltrials.gov/ct2/show/NCT01143064?term=BHR+Pharma|website=[[ClinicalTrials.gov]]|date=June 14, 2010|access-date=August 21, 2022}}</ref><ref>{{cite web|last=Begley|first=Sharon|title=Revealing brain damage from battlefield to playing field|url=https://www.reuters.com/article/brain-trauma-idUSL1E8GGJ8O20120516|publisher=[[Reuters]]|access-date=May 14, 2012|date=May 16, 2012|archive-date=February 16, 2013|archive-url=https://archive.today/20130216171947/http://www.reuters.com/article/2012/05/16/brain-trauma-idUSL1E8GGJ8O20120516|url-status=live}}</ref> The [[Food and Drug Administration]] has promised to fast-track the approval process for BHR-100 if the findings are positive.<ref>{{cite news|last=Tuller|first=David|title=A Hormonal Remedy for Brain Injuries Is Explored|url=https://www.nytimes.com/2012/06/19/health/study-tests-if-progesterone-can-save-lives-after-brain-injury.html?_r=1|work=[[The New York Times]]|date=June 18, 2012|access-date=June 19, 2011|url-access=subscription|url-status=live|archive-url=https://web.archive.org/web/20120625004004/http://www.nytimes.com/2012/06/19/health/study-tests-if-progesterone-can-save-lives-after-brain-injury.html?_r=1|archive-date=June 25, 2012}}</ref> The drug is one of four compounds in late-stage development to combat TBI, and is the only one expected to reach the market before 2019.<ref>{{cite web|title=TBI Research Creates Opportunities for Pharma|url=http://www.dddmag.com/news/2012/06/TBI-research-creates-opportunities-pharma|work=[[Drug Discovery & Development]]|date=June 1, 2012|access-date=June 19, 2012|archive-url=https://web.archive.org/web/20121023160445/http://www.dddmag.com/news/2012/06/TBI-research-creates-opportunities-pharma|archive-date=October 23, 2012}}</ref> |
|||
== Controversy == |
== Controversy == |
||
Revision as of 09:01, 15 April 2024
 | The topic of this article may not meet Wikipedia's notability guidelines for companies and organizations. (February 2013) |
Besins Healthcare, a privately held pharmaceutical company, was established in 1885 by Abel Besins and Joseph Lebeau in Paris, France. Today, the company's headquarters are located in Monaco. Specialising in hormone replacement therapies, Besins Healthcare addresses health issues related to fertility, menopause and testosterone deficiency.[1] Over the past two decades, it has expanded its operations internationally, now having a direct presence in 22 countries and distributing products in over 100 markets.[2] Besins Healthcare operates through its fully owned affiliate, Ascend Therapeutics, in the US..[2]
The company reports a revenue of €500 million in 2023 and employs more than 1,500 individuals globally.
Controversy
AG Rosenblum Sues Pharmaceutical Giants AbbVie and Besins
In November 2022, Oregon Attorney General Ellen Rosenblum sued AbbVie, Abbott Laboratories, Unimed Pharmaceuticals. The lawsuit alleges that the four pharmaceutical companies, which held the exclusive patent for brand-name AndroGel, filed baseless lawsuits to monopolize the market and prevent competitors from entering, which resulted in sky-high prices.[3]
Federal Trade Commission v. AbbVie
The FTC filed a complaint in federal district court in September 2014 charging that AbbVie Inc. and its partner Besins Healthcare Inc. illegally blocked American consumers’ access to lower-cost alternatives to Androgel by filing baseless patent infringement lawsuits against potential generic competitors. In a June 2018 decision, the U.S. District Court for the Eastern District of Pennsylvania ruled that sham litigation was used to create a monopoly.[4]
References
- ^ Makar, A. B.; McMartin, K. E.; Palese, M.; Tephly, T. R. (1975-06). "Formate assay in body fluids: application in methanol poisoning". Biochemical Medicine. 13 (2): 117–126. doi:10.1016/0006-2944(75)90147-7. ISSN 0006-2944. PMID 1.
{{cite journal}}: Check date values in:|date=(help) - ^ a b Bose, K. S.; Sarma, R. H. (1975-10-27). "Delineation of the intimate details of the backbone conformation of pyridine nucleotide coenzymes in aqueous solution". Biochemical and Biophysical Research Communications. 66 (4): 1173–1179. doi:10.1016/0006-291x(75)90482-9. ISSN 1090-2104. PMID 2.
- ^ Nguyen, Ally (2022-11-10). "AG Rosenblum Sues Pharmaceutical Giants AbbVie and Besins". Oregon Department of Justice. Retrieved 2023-01-21.
- ^ "AbbVie Inc., et al". Federal Trade Commission. 2014-09-08. Retrieved 2023-01-21.
